Overview

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC

Status:
Recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

A study to evaluate nivolumab + chemotherapy or nivolumab/ BMS-986205 + chemotherapy followed by continued Immuno-Oncology therapy after radical cystectomy (RC) compared with neoadjuvant standard of care (SOC) chemotherapy alone in patients with muscle-invasive bladder cancer (MIBC)

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Gemcitabine
Linrodostat
Nivolumab